Veeva RIM Propels Over 450 Companies Towards Faster Market Launches
As the pharmaceutical industry grapples with increasing regulatory demands, Veeva Systems has become a beacon of efficiency, announcing that more than 450 companies are employing its Regulatory Information Management (RIM) platform. Among these adopters, an impressive 19 of the top 20 biopharmaceutical firms have integrated Veeva RIM into their regulatory strategies.
Veeva RIM is recognized for its advanced capabilities, facilitating streamlined processes across all stages of the regulatory lifecycle. This includes functionalities that encourage continuous publishing, which has been embraced by over 85 organizations. The aim? To reduce rework and bottlenecks, thereby accelerating submission timelines. In a landscape where time can be the difference between success and failure, these improvements are crucial.
The scale of adoption highlights a significant shift in how regulatory teams operate. By harnessing the power of cloud technology, Veeva RIM not only enhances efficiency but also fosters collaboration domestically and internationally. Advanced integration with platforms such as Accumulus Technologies and DNAnexus is set to further streamline interactions with regulatory bodies across the globe. Francisco Nogueira, CEO of Accumulus Technologies, notes that their partnership with Veeva aims to revolutionize information sharing, enabling seamless regulatory submissions that can expedite access to treatments for patients.
Thomas Laur, CEO of DNAnexus, echoed this sentiment, emphasizing the importance of data sharing capabilities for inter-agency collaboration. With Veeva RIM, companies benefit from best-in-class tools that make regulatory processes smoother, and ultimately, pave the way for faster approvals of new therapeutics.
These partnerships mark an ongoing commitment to innovation and connectivity in the life sciences sector, ensuring that Veeva remains at the forefront of an industry that is always evolving. Each improvement not only enhances the user experience for the companies involved but also optimizes patient outcomes.
"Regulatory teams are adopting new product innovations to continuously improve efficiency and reduce cycle times," said Marc Gabriel, Veeva's Vice President of Regulatory. This statement encapsulates the core purpose of Veeva RIM: providing a comprehensive end-to-end solution that not only meets regulatory requirements but also strategically positions companies for greater success in an increasingly complex regulatory environment.
The Veeva Development Cloud serves as the backbone for this approach, centralizing critical processes such as clinical data management, quality assurance, regulatory compliance, and safety monitoring. By having a unified platform, companies can ensure a seamless data flow that aids in regulatory submissions and compliance monitoring, which is especially vital as regulatory agencies become more stringent.
Veeva's approach emphasizes the importance of balancing stakeholder interests. As a Public Benefit Corporation, Veeva is dedicated to not only achieving product excellence but also ensuring that its innovations yield benefits for customers, employees, and shareholders alike. This holistic outlook reinforces Veeva's reputation as a trusted partner in the life sciences industry.
In summary, with over 450 companies adopting Veeva RIM to enhance their regulatory management processes, it is evident that Veeva is not just providing a tool; it is shaping the future of regulatory strategy in biopharmaceuticals. The continuous innovations and partnerships being forged are not only set to accelerate time to market, they also promise to connect a growing network of regulatory agencies, thereby optimizing the journey from development to effective patient access. As Veeva RIM continues to evolve, so too will the landscape of regulatory management in life sciences, heralding a new era of efficiency and collaboration that benefits the entire industry.
Veeva RIM is recognized for its advanced capabilities, facilitating streamlined processes across all stages of the regulatory lifecycle. This includes functionalities that encourage continuous publishing, which has been embraced by over 85 organizations. The aim? To reduce rework and bottlenecks, thereby accelerating submission timelines. In a landscape where time can be the difference between success and failure, these improvements are crucial.
The scale of adoption highlights a significant shift in how regulatory teams operate. By harnessing the power of cloud technology, Veeva RIM not only enhances efficiency but also fosters collaboration domestically and internationally. Advanced integration with platforms such as Accumulus Technologies and DNAnexus is set to further streamline interactions with regulatory bodies across the globe. Francisco Nogueira, CEO of Accumulus Technologies, notes that their partnership with Veeva aims to revolutionize information sharing, enabling seamless regulatory submissions that can expedite access to treatments for patients.
Thomas Laur, CEO of DNAnexus, echoed this sentiment, emphasizing the importance of data sharing capabilities for inter-agency collaboration. With Veeva RIM, companies benefit from best-in-class tools that make regulatory processes smoother, and ultimately, pave the way for faster approvals of new therapeutics.
These partnerships mark an ongoing commitment to innovation and connectivity in the life sciences sector, ensuring that Veeva remains at the forefront of an industry that is always evolving. Each improvement not only enhances the user experience for the companies involved but also optimizes patient outcomes.
"Regulatory teams are adopting new product innovations to continuously improve efficiency and reduce cycle times," said Marc Gabriel, Veeva's Vice President of Regulatory. This statement encapsulates the core purpose of Veeva RIM: providing a comprehensive end-to-end solution that not only meets regulatory requirements but also strategically positions companies for greater success in an increasingly complex regulatory environment.
The Veeva Development Cloud serves as the backbone for this approach, centralizing critical processes such as clinical data management, quality assurance, regulatory compliance, and safety monitoring. By having a unified platform, companies can ensure a seamless data flow that aids in regulatory submissions and compliance monitoring, which is especially vital as regulatory agencies become more stringent.
Veeva's approach emphasizes the importance of balancing stakeholder interests. As a Public Benefit Corporation, Veeva is dedicated to not only achieving product excellence but also ensuring that its innovations yield benefits for customers, employees, and shareholders alike. This holistic outlook reinforces Veeva's reputation as a trusted partner in the life sciences industry.
In summary, with over 450 companies adopting Veeva RIM to enhance their regulatory management processes, it is evident that Veeva is not just providing a tool; it is shaping the future of regulatory strategy in biopharmaceuticals. The continuous innovations and partnerships being forged are not only set to accelerate time to market, they also promise to connect a growing network of regulatory agencies, thereby optimizing the journey from development to effective patient access. As Veeva RIM continues to evolve, so too will the landscape of regulatory management in life sciences, heralding a new era of efficiency and collaboration that benefits the entire industry.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.